🌎 Qiagen NV is a Dutch holding company and global provider of molecular diagnostics and life sciences solutions.

Main activities:

Sample processing techniques: Extraction and processing of DNA, RNA and proteins from blood, tissue and other materials.

Analytical techniques: Preparing biomolecules for analysis.

Bioinformatics: Software and knowledge bases for interpreting data and its practical applications.

Main products and platforms:

QuantiFERON: A test to diagnose latent tuberculosis.

QIAstat-Dx: A related test system for the simultaneous detection of multiple pathogens.

QIAcuity: digital PCR system.

QIAGEN Digital Insights (QDI): Department of Bioinformatics.

The company serves more than 500,000 customers worldwide in the life sciences (academic, pharmaceutical R&D, forensics) and molecular diagnostics fields.

In the second quarter of 2025, revenue was $533.54 million, beating expectations.

The company expects adjusted operating margin to reach 31% by mid-2025, exceeding its original 2028 forecast.

Management raised its full-year 2025 adjusted earnings per share forecast to about $2.35 per year, compared with $2.28 previously.

In 2025, Qiagen’s entire QIAstat-Dx product portfolio received CE-IVDR certification in Europe and the QIAstat-Dx Rise system received U.S. Food and Drug Administration (FDA) approval.

The stock is trading broadly sideways at the upper boundary of the price channel.

Source link